Next-Generation Sequencing for Advanced Breast Cancer: What the Way to Go?
Author:
Publisher
Springer International Publishing
Link
https://link.springer.com/content/pdf/10.1007/978-3-031-33602-7_13
Reference42 articles.
1. Condorelli R et al (2019) Genomic alterations in breast cancer: level of evidence for actionability according to ESMO scale for clinical actionability of molecular targets (ESCAT). Annal Oncol 30(3)
2. Crimini E et al (2021) Precision medicine in breast cancer: from clinical trials to clinical practice. Cancer Treat Rev 98
3. Mateo J et al (2018) A Framework to rank genomic alterations as targets for cancer precision medicine: the ESMO scale for clinical actionability of molecular targets (ESCAT). Ann Oncol 29(9)
4. Palmero R et al (2021) Biomarker discovery and outcomes for comprehensive cell-free circulating tumour DNA versus standard-of-care tissue testing in advanced non-small-cell lung cancer. JCO Precis Oncol 5(5):93–102. https://pubmed.ncbi.nlm.nih.gov/34994593/. Accessed 2 June 2022
5. Paz-Ares L et al (2022) Genomic testing among patients with newly diagnosed advanced non-small cell lung cancer in the United States: a contemporary clinical practice patterns study. Lung Cancer (Amsterdam, Netherlands) 167:41–48. https://pubmed.ncbi.nlm.nih.gov/35397297/. Accessed 2 June 2022
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3